Abstract
Interactions with the hepatic cytochrome P-450 microsomal enzyme system, as evidenced by statistically significant changes in pharmacokinetic parameters, have been described with some H2-receptor antagonists. Omeprazole is the first of a new class of antisecretory agents inhibiting gastric secretion by blocking hydrogen potassium ATPase. Omeprazole contains a benzimidazole moiety and thus has the potential to interact with the cytochrome P-450 enzyme group.In vitro, in vivo and human clinical studies have assessed whether such an interaction occurs, and the potential clinical consequences, in patients receiving omeprazole therapy.In vitro studies have demonstrated that omeprazole influencesO-deethylation andN-demethylation in liver microsomes and the clearance and elimination half-life of antipyrine in isolated perfused liver preparations. Overall, the studies reviewed suggest that omeprazole has a differential affinity toward specific cytochrome P-450 isozymes.In vivo animal studies have demonstrated that omeprazole prolongs pentobarbital sleep times and half-life and decreases [14C]-aminopyrine elimination. Human clinical studies have not demonstrated the “all or none” effect of omeprazole on cytochrome P-450-mediated drug interactions, as is seen with cimetidine. These studies confirmin vitro findings that omeprazole is a differential inhibitor of drug metabolism: interactions have been demonstrated with the model drugs aminopyrine and antipyrine, and the therapeutic drugs diazepam, phenytoin, and warfarin but not with theophylline or propranolol. Although caution should be exercised when initiating omeprazole therapy in patients taking concomitant diazepam, warfarin, and phenytoin, clinically significant drug interactions appear unlikely.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Sax MJ: Clinically important adverse effects and drug interactions with H2-receptor antagonists: An update. Pharmacotherapy 7:1105–1155, 1987
Kirch W, Hoensch H, Janisch HD: Interactions and noninteractions with ranitidine. Clin Pharmacokinet 9:493–510, 1984
Humphries TJ: Famotidine: A notable lack of drug interactions. Scand J Gastroenterol 22 (suppl 134):55–60, 1987
Friedman G: GI drug column. Omeprazole. Am J Gastroenterol 82:188–191, 1987
Jensen JC, Gugler R: Inhibition of human liver enzyme cytochrome P-450 by omeprazole. Br J Clin Pharmacol 21:320–330, 1986
Webster LK, Jones DB, Smallwood RA: How potent is the inhibition of drug metabolism by omeprazole? Lancet 2:761, 1984
Miwa GT:In vitro spectral and kinetic studies on the interaction of omeprazole with cytochrome P-450. Data on file at Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486
Henry DA, Gerkens JF, Brent P, Somerville K: Inhibition of drug metabolism by omeprazole. Lancet 2:46–47, 1984
Henry DA, Somerville KW, Kitchingman GK, Langman MJS: Omeprazole: Effects on oxidative drug metabolism. Br J Clin Pharmacol 18:195–200, 1984
Merck Sharp & Dohme Research Laboratories: Data on File. West Point, Pennsylvania 19486
Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism. Gastroenterology 89:1235–1241, 1985
Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Langman MJS, Williams J, Richens A: Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 24:543–545, 1987
Sutfin T, Balmer K, Bostrom N, Eriksson S, Hoglund P, Paulsen O: Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11:176–184, 1989
Gugler R, Jensen JC: Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolismin vitro. Pharmacol Ther 33: 133–137, 1987
Merck Sharp & Dohme Research Laboratories: Data on file. West Point, Pennsylvania 19486
Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S: Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 33:369–373, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Humphries, T.J. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digest Dis Sci 36, 1665–1669 (1991). https://doi.org/10.1007/BF01296606
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01296606